contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforias-partner-network-expands-to-canada

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Head of Nordic ER Development, Analyst

Antti Luiro

Analyst

Frans-Mikael Rostedt

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Well, what do you know, it hit the mark! The hint was this funding, where a project by a Dana-Farber researcher matched a bit too precisely what Aiforia’s earlier press release opened up about.                   MLSC – 22 Dec 25              Healey-Driscoll Administration Announces More Than $20 Million in Life...    Stay up to date with news, announcements, and insights from the Massachusetts Life Sciences Center, including programs, funding initiatives, and industry updates.         Est. reading time: 5 minutes

aiforia.com              Aiforia Announces Collaboration on Bladder Cancer Research with Renowned...    Aiforia and Dana-Farber Cancer Institute partner to advance bladder cancer treatment using Aiforia® Create-built AI solution.

No name has been published. Mayo probably isn’t it, someone else, and a strong candidate could be https://www.dana-farber.org/  Aiforia is currently recruiting in Boston for that location. However, what interests me most right now is how Aiforia is progressing with its funding and growth strategy; discussions with the largest owners who thwarted the offering are likely underway.

That reminds me, has the name of that esteemed American cancer institute been published yet, the one we made an agreement with at the end of the year? I haven’t been able to find it anywhere, or maybe I’ve completely missed it

aiforia.com              Mayo Clinic study: AI is enhancing Ki-67 scoring in breast cancer pathology    Explore manual Ki-67 scoring challenges and Aiforia® Create-built AI model’s excellent performance in a Mayo Clinic study of 1,877 breast cancer cases.                             The company’s own publication from the breast cancer front in pathology.

Inside Precision Medicine – 7 Apr 26              The Digital Path to AI in Cancer Care    The ability of AI to interpret and annotate tumor sample slides that have been digitized is taking center stage.                             This news also prominently features many partners associated with Aiforia, as well as competitors. However, the field is experiencing strong growth, and things are constantly happening. I guess I have to trust this, as I’ve committed to it. It’s just a shame that pathology is such a mess that my medical understanding and the significance of collaboration models for the company are somewhat exhausted. “Help, help, heeelp!!!” PP once cried on television.

As I was idly browsing Aiforia’s old news, I suddenly came across this win from 2023. Aiforia receives a contract award to provide AI solutions for 25 NHS hospitals of the PathLAKE Plus consortium in the UK  The duration of the individual contracts with the hospitals will be three years, with a possible three-year extension. Could this UK recruitment also apply to this potential three-year extension? Who knows, Barbie doesn’t. It would be nice to get extensions and sell a couple of new applications alongside. The estimated volumes mentioned in the tender were 12888 cases annually (109166 slides) for prostate, and 2522 cases (28880 slides) annually for lung cancer PD-L1, with these numbers expected to increase annually. So, an estimated 138046 samples initially with two applications, and the number was expected to increase annually. This means almost a million-euro contract at the start, with a sample price of 5-10 euros.

Aiforia Technologies

New partnerships are naturally positive for Aiforia, as they reflect the attractiveness of the company's image analysis solutions in the digital pathology market and improve the prerequisites for winning new customers. 

Translation: Original published in Finnish on 03/18/2025 at 10:23 am EET
The company today&#xa0;<a href="https://www.inderes.se/releases/aiforia-expands-its-global-reach-through-a-partnership-with-quorum-technologies-in-canada" target="_blank" rel="noopener">announced</a> a partnership with the Canadian Quorum Technologies. Based on the announcement, Quorum will act as an integrator in the implementation of Aiforia&#x2019;s solution and support sales.
The partner channel is important for the company, as building own direct sales in all markets would not, in our view, be practical or financially sensible as the market is forming rapidly. Utilizing integrators also allows Aiforia to ramp up more customers simultaneously.
New partnerships are naturally positive for Aiforia, as they reflect the attractiveness of the company&apos;s image analysis solutions in the digital pathology market and improve the prerequisites for winning new customers. Our estimates expect the company to successfully implement its growth strategy, including continuous customer wins and accelerating revenue growth, so the release does not affect our view of the company.

	2024	25e	26e
Revenue	2.9	4.7	7.6
growth-%	18.9 %	65.7 %	60.0 %
EBIT (adj.)	-12.2	-11.9	-12.0
EBIT-% (adj.)	-427.8 %	-252.9 %	-158.1 %
EPS (adj.)	-0.41	-0.36	-0.36
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Aiforia’s partner network expands to Canada

Login required

Key Estimate Figures10.03.2025

Forum discussions